Q&A for Integrating MOUD with 12-Step and Mutual Help Programs enduring module is a recording from the live Regularly Scheduled Series dated September 9, 2021. If you claimed credit for this session at the live meeting, you should not claim credit for this module.

Faculty

Needs Statement

Prior to the development of FDA approved medications for Opioid Use Disorder, twelve step programs provided one of the only options for managing opioid use disorder. As the prevalence of Opioid use disorder and opioid related deaths has increased, so has the need for treatment that addresses the biopsychosocial aspects of the disease.

Patients with OUD taking evidence-based medications for OUD face challenges when integrating their medication treatment with traditional twelve step programs whose definition of “abstinence” conflicts with taking medications to treat substance use disorders.

There has been relatively little research into the patient experience with traditional 12 step programs and MOUD. However, common challenges have been identified.

Understanding common challenges for patients on MOUD can empower providers to help patients navigate strategies for integrating MOUD into mutual support groups.

Target Audience

Physicians, Nurses, Nurse Practitioners, Physician Assistants, Pharmacists, Social Workers

Objectives

Upon completion of this activity, participants will be able to:

• Identify common twelve step and mutual support programs, and explain the philosophy of abstinence based twelve step programs.
• Explain common challenges persons on MOUD face when integrating medication and abstinence based programs
• Explain strategies for integrating MOUD into abstinent based programs and explore alternatives to traditional twelve step programs.

Accreditation

In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME
This enduring material is designated for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This training has been approved by the KBML as meeting the statutory requirements of HB1. 0821-H1.5-UKHC28b

IPE Competencies

• Values/Ethics for Interprofessional Practice
• Roles/ Responsibilities
• Interprofessional Communication
• Teams and Teamwork

CPE
This knowledge-based activity will award 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

ASWB ACE
As a Jointly Accredited Organization, UK HealthCare CECentral is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. UK HealthCare CECentral maintains responsibility for this course. Social workers completing this course receive 1.00 general continuing education credit.

CNE
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 nursing contact hour.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months.  An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. 

None of the planners, faculty, and others in control of educational content for this educational activity have relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgement

In collaboration with UK Substance Use Research Priority Area.